{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:54:48Z","timestamp":1787698488665,"version":"build-2784847793"},"reference-count":63,"publisher":"Society of Nuclear Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,2,3]]},"published-print":{"date-parts":[[2025,6]]},"DOI":"10.2967\/jnumed.124.268818","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T16:15:21Z","timestamp":1740672921000},"page":"833-838","source":"Crossref","is-referenced-by-count":13,"title":["The Role of PSMA PET Parameters as Biomarkers for Response to PSMA-Targeted Radiopharmaceutical Therapy"],"prefix":"10.2967","volume":"66","author":[{"given":"Vishnu","family":"Murthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Gafita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremie","family":"Calais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"2025060410151032000_66.6.833.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"2025060410151032000_66.6.833.2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ymeth.2017.06.026","article-title":"PSMA ligands in prostate cancer: probe optimization and theranostic applications","volume":"130","author":"Lutje","year":"2017","journal-title":"Methods."},{"key":"2025060410151032000_66.6.833.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30314-7"},{"key":"2025060410151032000_66.6.833.4","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA. Oncol."},{"key":"2025060410151032000_66.6.833.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2025060410151032000_66.6.833.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"2025060410151032000_66.6.833.7","doi-asserted-by":"crossref","unstructured":"Hofman MS Emmett L Sandhu S .; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol. 2024;25:99\u2013107.","DOI":"10.1016\/S1470-2045(23)00529-6"},{"key":"2025060410151032000_66.6.833.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265077"},{"key":"2025060410151032000_66.6.833.9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263441"},{"key":"2025060410151032000_66.6.833.10","doi-asserted-by":"crossref","first-page":"1382582","DOI":"10.3389\/fonc.2024.1382582","article-title":"Comparison of 18F-DCFPyL and 68Ga-PSMA-11 for 177Lu-PSMA-617 therapy patient selection","volume":"14","author":"Yadav","year":"2024","journal-title":"Front Oncol."},{"key":"2025060410151032000_66.6.833.11","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","article-title":"PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis","volume":"48","author":"Seifert","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060410151032000_66.6.833.12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264489"},{"key":"2025060410151032000_66.6.833.13","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/jamaoncol.2018.1093","article-title":"Phase 3 assessment of the automated bone scan index as a prognostic imaging biomarker of overall survival in men with metastatic castration-resistant prostate cancer: a secondary analysis of a randomized clinical trial","volume":"4","author":"Armstrong","year":"2018","journal-title":"JAMA. Oncol."},{"key":"2025060410151032000_66.6.833.14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219352"},{"key":"2025060410151032000_66.6.833.15","doi-asserted-by":"crossref","first-page":"e233460","DOI":"10.1148\/radiol.233460","article-title":"Quantitative 68Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following 177Lu-PSMA-617 (VISION Trial)","volume":"312","author":"Kuo","year":"2024","journal-title":"Radiology."},{"key":"2025060410151032000_66.6.833.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.261906"},{"key":"2025060410151032000_66.6.833.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265242"},{"key":"2025060410151032000_66.6.833.18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267014"},{"key":"2025060410151032000_66.6.833.19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cpet.2009.05.002","article-title":"FDG PET in prostate cancer","volume":"4","author":"Jadvar","year":"2009","journal-title":"PET Clin."},{"key":"2025060410151032000_66.6.833.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"2025060410151032000_66.6.833.21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0587"},{"key":"2025060410151032000_66.6.833.22","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1007\/s00259-020-05160-8","article-title":"Prognostic implications of dual tracer PET\/CT: PSMA ligand and [18F]FDG PET\/CT in patients undergoing [177Lu]PSMA radioligand therapy","volume":"48","author":"Michalski","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060410151032000_66.6.833.23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00605-2"},{"key":"2025060410151032000_66.6.833.24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.236414"},{"key":"2025060410151032000_66.6.833.25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268167"},{"key":"2025060410151032000_66.6.833.26","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266842"},{"key":"2025060410151032000_66.6.833.27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265952"},{"key":"2025060410151032000_66.6.833.28","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00259-018-4236-4","article-title":"Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer","volume":"46","author":"Grubmuller","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060410151032000_66.6.833.29","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2018.11.016","article-title":"Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer","volume":"75","author":"Heck","year":"2019","journal-title":"Eur Urol."},{"key":"2025060410151032000_66.6.833.30","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/pros.24549","article-title":"PSMA-heterogeneity in metastatic castration-resistant prostate cancer: circulating tumor cells, metastatic tumor burden, and response to targeted radioligand therapy","volume":"83","author":"Derlin","year":"2023","journal-title":"Prostate."},{"key":"2025060410151032000_66.6.833.31","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266167"},{"key":"2025060410151032000_66.6.833.32","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.7150\/thno.96322","article-title":"Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients","volume":"14","author":"Slootbeek","year":"2024","journal-title":"Theranostics."},{"key":"2025060410151032000_66.6.833.33","doi-asserted-by":"crossref","first-page":"e2400645","DOI":"10.1200\/PO-24-00645","article-title":"Cancer-control outcomes of patients with metastatic castration-resistant prostate cancer with BRCA gene or tumor suppressor mutations undergoing 177-lutetium prostate-specific membrane antigen radioligand therapy","volume":"8","author":"Wenzel","year":"2024","journal-title":"JCO Precis Oncol."},{"key":"2025060410151032000_66.6.833.34","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00274-6"},{"key":"2025060410151032000_66.6.833.35","first-page":"P400","article-title":"Extension of a 68Ga-PSMA PET-based nomogram for outcome prediction of 177Lu-PSMA radioligand therapy for the use of 18F-rhPSMA-7.3 [abstract]","volume":"64(suppl 1)","author":"Rauscher","year":"2023","journal-title":"J Nucl Med."},{"key":"2025060410151032000_66.6.833.36","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1200\/JCO.2023.41.16_suppl.5028","article-title":"Building a predictive model for outcomes with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer using VISION data: preliminary results","volume":"41","author":"Herrmann","year":"2023","journal-title":"J Clin Oncol."},{"key":"2025060410151032000_66.6.833.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.03.081"},{"key":"2025060410151032000_66.6.833.38","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.057307"},{"key":"2025060410151032000_66.6.833.39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2025060410151032000_66.6.833.40","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s13139-018-0548-3","article-title":"Evaluation of RECIST, PERCIST, EORTC, and MDA criteria for assessing treatment response with Ga68-PSMA PET-CT in metastatic prostate cancer patient with biochemical progression: a comparative study","volume":"52","author":"Gupta","year":"2018","journal-title":"Nucl Med Mol Imaging."},{"key":"2025060410151032000_66.6.833.41","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.233817"},{"key":"2025060410151032000_66.6.833.42","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.260836"},{"key":"2025060410151032000_66.6.833.43","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263072"},{"key":"2025060410151032000_66.6.833.44","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267234"},{"key":"2025060410151032000_66.6.833.45","doi-asserted-by":"crossref","first-page":"e222148","DOI":"10.1148\/radiol.222148","article-title":"Response evaluation criteria in PSMA PET\/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer","volume":"308","author":"Gafita","year":"2023","journal-title":"Radiology."},{"key":"2025060410151032000_66.6.833.46","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.2024.42.4_suppl.48","article-title":"Updated automated PROMISE assessment: treatment response evaluation based on PSMA PET\/CT","volume":"42","author":"Benitez","year":"2024","journal-title":"J Clin Oncol."},{"key":"2025060410151032000_66.6.833.47","doi-asserted-by":"crossref","first-page":"S972","DOI":"10.1016\/j.annonc.2023.09.2747","article-title":"1797P Application of novel machine learning model in [68Ga] Ga-PSMA-11 PET\/CT: predicting survival in oligometastatic prostate cancer patients [abstract]","volume":"34","author":"Dell\u2019Oro","year":"2023","journal-title":"Ann Oncol."},{"key":"2025060410151032000_66.6.833.48","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265155"},{"key":"2025060410151032000_66.6.833.49","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266702"},{"key":"2025060410151032000_66.6.833.50","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265874"},{"key":"2025060410151032000_66.6.833.51","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1007\/s00259-023-06382-2","article-title":"Prognostic utility of RECIP 1.0 with manual and AI-based segmentations in biochemically recurrent prostate cancer from [68Ga]Ga-PSMA-11 PET images","volume":"50","author":"Kendrick","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060410151032000_66.6.833.52","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1007\/s00259-022-05882-x","article-title":"Measuring response in metastatic castration-resistant prostate cancer using PSMA PET\/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria","volume":"49","author":"Gafita","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060410151032000_66.6.833.53","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.3390\/jcm10194396","article-title":"Total lesion glycolysis improves tumor burden evaluation and risk assessment at diagnosis in Hodgkin lymphoma","volume":"10","author":"Herraez","year":"2021","journal-title":"J Clin Med."},{"key":"2025060410151032000_66.6.833.54","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00259-023-06476-x","article-title":"Change in total lesion PSMA (TLP) during [177Lu]Lu-PSMA-617 radioligand therapy predicts overall survival in patients with mCRPC: monocentric evaluation of a prospective registry","volume":"51","author":"Burgard","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060410151032000_66.6.833.55","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1007\/s00259-021-05594-8","article-title":"Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET\/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy","volume":"49","author":"Rosar","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060410151032000_66.6.833.56","doi-asserted-by":"crossref","first-page":"1339160","DOI":"10.3389\/fmed.2023.1339160","article-title":"Change of glucometabolic activity per PSMA expression predicts survival in mCRPC patients non-responding to PSMA radioligand therapy: introducing a novel dual imaging biomarker","volume":"10","author":"Burgard","year":"2024","journal-title":"Front Med (Lausanne)."},{"key":"2025060410151032000_66.6.833.57","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264677"},{"key":"2025060410151032000_66.6.833.58","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264398"},{"key":"2025060410151032000_66.6.833.59","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00259-023-06536-2","article-title":"Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT\/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study","volume":"51","author":"Neubauer","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060410151032000_66.6.833.60","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1007\/s00259-024-06718-6","article-title":"Same-day post-therapy imaging with a new generation whole-body digital SPECT\/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer","volume":"51","author":"Song","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060410151032000_66.6.833.61","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267208"},{"key":"2025060410151032000_66.6.833.62","doi-asserted-by":"crossref","first-page":"17588359231156392","DOI":"10.1177\/17588359231156392","article-title":"Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)","volume":"15","author":"Emmett","year":"2023","journal-title":"Ther Adv Med Oncol."},{"key":"2025060410151032000_66.6.833.63","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267955"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.268818","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T17:16:03Z","timestamp":1749057363000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.268818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":63,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,2]]},"published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.2967\/jnumed.124.268818"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.268818","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}